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BACKGROUND:  
Recent advances in science, technology and informatics have led to a rapid expansion of genomic 
research worldwide. This research has yielded an unprecedented volume of data including both 
Individual Research Results (IRRs) - ‘pertinent results from research’ that may have clinical relevance 
for individuals and their families, and Incidental findings (IFs), which can best be understood as 
“unanticipated discoveries” made during the course of an investigation but are outside the scope of 
the research (1). Over the last decade, the management of the disclosure of both IRRs and IFs in the 
context of genomic research has been the subject of extensive scientific, ethical and legal 
commentary and critique (2, 3) and has emerged as a major challenge for biobanks (also known as 
tissue banks and biorepositories)(4-12). Competing views amongst scholars as to the circumstances in 
which disclosure should be made have been articulated in the international literature. These range 
from arguments for a definite duty to disclose in specified circumstances,(3) to more cautious and 
qualified stances based around principles of ‘harm minimisation’ (13, 14). Little is known internationally 
however, as to how the general public, as potential donors, view the issues surrounding the return of 
genetic research results. 
 
Even fewer Australian studies have directly explored the concerns of the general public and/or 
biobank tissue donors (11, 15-17). Studies have largely mirrored those conducted in Ireland (17) and 
Sweden (18, 19) which found that the general public were supportive of the retention of donated tissue 
for future unspecified research approv and were convinced that biobanks and the linkage of 
biological, clinical and population data provided a vital contribution to the acquisition of new 
knowledge. Importantly, these initial studies also suggest that there is public support for the 
appropriate disclosure of IRRs and IFs from biobank related research. A preliminary study by Fleming 
(2007) reported that the majority of both the general public (n=464) and cancer tissue donor (n=93) 
respondents wished to be informed about the general results of the research (82% of the public v 
62% of donors), individual results that would suggest that they may have a possible predisposition 
for a genetic condition (84% of public v 83% of donors) and individual results that indicated that they 
may have an untreatable inheritable condition (75% of public and 72% of donors) (11).These findings 
are broadly consistent with a more recent and larger study among tissue donors arising from the 
International Sarcoma Kindred Study that examined attitudes towards genomic research amongst 
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individuals diagnosed with sarcoma, their blood relatives and proband spouses (20). This study found 
that all donors wanted to receive information (90-94%) about monogenic or polygenic conditions in 
which risk could be modified, but that for monogenic conditions that were not preventable, sarcoma 
probands and blood relatives were less likely to want to receive information than non-blood relative 
spouses (66.5% vs 76%, p=0.05). 
AIMS:  
The aim of this research was to extend our understanding of the general public’s preferences for 
disclosure of the results of genomic research, including IRRs and IFs by surveying a nationally 
representative sample of Australians. Specifically, we also sought to investigate the degree of public 
support for different models of disclosure including; non-disclosure, mandated disclosure, or the 
disclosure of certain findings and not others according to their salience or to the expressed 
preferences of the biobank donor. 
 
METHODS 
Participants and procedure 
A total of 800 Australians over the age of 18 years and who could speak English participated in a 
computer assisted telephone interview (CATI). The study was approved by the University of 
Swinburne Human Research Ethics Committee (SUHREC2013/002). Telephone numbers were 
randomly generated by Samplworx, and were designed to represent the proportion of residents 
residing in each Australian State and Territory. The response rates according to the American 
Association of Public Opinion Research’s (2009) definitions and calculations (i.e., RR1 – RR4) (AAPOR, 
2009) ranged from 12% - 17%, which is typical for Australian national surveys conducted via CATI, 
random digit dialling (RDD) and cold calling members of the public without introductory letters[1] 
Because 1000’s of randomly generated numbers are used with only a small proportion resulting in 
contact with an eligible household or person, the response rates calculated from this internationally 
recognised formula are significantly underestimated. This is exacerbated by the known difficulty with 
estimating the proportion of potentially eligible numbers not resulting in an interview (see: 
http://www.aapor.org/AAPORKentico/AAPOR_Main/media/MainSiteFiles/ERATE09.pdf). 
The sample was relatively representative of the Australian population in terms of the states and 
territory of residence, education (43.4% had a university education) and ethnicity (87.4% described 
their nationality as Australian). Most of the sample had children (84.0%) and were either married or 
in a defacto relationship (66.4%; 12.6% were single, 9.6% were separated or divorced, 10.8% were 
widowed). A total of 84.0% described their health as being good to excellent (19.0% excellent, 33.9% 
very good, and 31.1% good), with 12.0% describing their heath as fair and 3.4% as poor. In terms of 
spirituality, 24.5% described it as being very important to them, 21.9% as quite important, 28.0% as 
not very important and 23.4% as not at all important. 
 
The sample was, however, overrepresented by older people (M = 58.17, SD = 15.53, Range = 18 - 94) 
and females (66.0%). The current research therefore utilised a sample weight for all analyses based 
on the Australian Bureau of Statistics proportions for age group and gender. Reflecting the bias in 
age, a total of 38.5% of the sample were retired, with 48.5% currently employed, 6.6% engaged in 
home duties, 2.5% were full-time students, 1.0% were on a disability pension and 5.3% were 
unemployed. 
 
 
                                                          
[1]
 Sending introductory letters before calling potential respondents can increase the response rate, but was 
not within the budget for this survey. 
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Measures 
The questionnaire instrument from which the CATI script evolved, was adapted from a survey tool 
previously developed by the first author for use within the Australian context (11).  The survey was 
identical in content and response options to the original measure, apart from minor wording changes 
to ensure it was suitable for a telephone interview (i.e., to explain scoring options, e.g., “By 
answering yes or no….”, and and lead in sentences such as “I would like to ask you about your 
thoughts on..”). Although a number of issues were addressed in the instrument, only those that 
related to the return of results are reported in this paper. Prior to these questions, respondents were 
informed that we were interested in “what Australians think about cancer research and tissue 
banks”, and were asked: 
I would like to ask you about your thoughts on the use of tissue samples in cancer research. Some 
cancer patients allow their blood or other tissue to be removed during surgery or a medical procedure 
to be stored for future research after all clinical testing on the sample has been completed. This is 
known as “tissue banking”. A cancer tissue bank is therefore a collection of biological samples taken 
from patients after a medical procedure. The collection is then made available for future research. 
After answering questions relating to their views on consent, storage of tissue, linkage of data, 
funding of biobanks, intention to participate and reasons for participation, respondents were asked, 
“By answering YES or NO, if you allowed your blood or tissue sample to be used for research, would 
you be interested in receiving the following types of research results?” The four options were 
randomly presented across the sample to avoid order effects, and were: general information 
regarding the results of the study overall, specific information obtained from your sample that may 
be important to your health or treatment, your own potential genetic risk of an inherited disease, 
and any incidental findings that weren’t directly related to your (potential) diagnosed condition. 
RESULTS 
A latent class analysis (LCA) was tested using MPLUS version 7 to identify potential groups of 
respondents with distinct patterns of interest in the four types of results. Cases with unsure 
responses to more than 30% of the four questions (n=21) were removed from the analysis and those 
who remained had their unsure responses imputed using MPLUS’s Bayesian analysis (Rubin, 1987) 
(n=779, weighted n = 706). The results clearly suggested 3 distinct groups of respondents consistent 
with the theoretical categorisation of Ravitsky and Wilfond, who described 3 approaches to the 
disclosure of IRRs and IFs: full disclosure (autonomy focussed), non-disclosure (research focussed) 
and contextual or specified approach to disclosure (result evaluation approach)(21). The sample size 
adjusted Bayesian Information Criterion (BIC) increased in value, the Bootstrap Lo–Mendell–Rubin 
(LMR) test became not significant from 3 to 4 classes (22) and entropy r for the 3 class solutions was 
.72, indicating good homogeneity within classes (23). The percentage of respondents indicating 
interest in receiving the four types of results for the total sample and the three classes is shown in 
Figure 1. 
The results in Figure 1 suggest that amongst the total sample, the majority of respondents would like 
access to all types of research results arising from the use of their blood/tissue in research. Primarily 
this involved general information that may be important to health or treatment, followed by the 
general research findings, then genetic risk information and finally incidental findings. Although less 
people expressed a desire to receive “any IFs that were not directly related to your (potential) 
diagnosed condition” (73.1%), there was a suggestion that most members of the public would still 
like to receive IFs. 
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Figure 1. Percentage of ‘Yes’ responses to the four return of results questions. Note. All n’s are 
weighted. Total unweighted n = 779. 
Specifically, the majority of the sample (i.e., Class 3) displayed an “autonomy focused” perspective in 
that they expressed an interest in receiving all types of results, including incidental findings.  A 
significant minority (i.e. Class 2) on the other hand tended to report a pattern more consistent with a 
“result evaluation” approach, with strong interest reported for receiving results that could have an 
impact upon health and treatment, and moderate interest in knowing their genetic risk for inherited 
disease, but weak interest in incidental findings and even weaker interest in general research 
findings. This class therefore appeared to emphasise results that were clinically valid and associated 
with findings that may have direct implication for their own health prevention. Although small, Class 
1 displayed a pattern of findings consistent with a “research focused” approach. These respondents 
were generally not in favour of receiving any results, apart from the general research findings where 
39.3% agreed they would be of interest. No one in this group was interested in findings that 
impacted on health, treatment or inherited diseases and only 18.6% reported being interested in 
incidental findings. 
A series of Chi-Square tests computed between class membership and the demographic variables 
found (all were significant at p<0.01) that the research focused class (Class 1) tended to be more 
likely to be from the Northern Territory, male and retired than would be expected by chance. The 
autonomy focused class (Class 3) tended to be more likely to be from New South Wales, female and 
to have a university education, and not be retired, while the result evaluation class (Class 2) were 
less likely to be from NSW and to have a university education. A one-way analysis of variance 
(ANOVA) with Student-Newman Keuls post hoc contrasts revealed that those in the autonomy- 
focused class (M = 51.16, SD = 17.80) were significantly (p<0.001) younger than those in the research 
focused (M= 60.5, SD = 17.82) and result evaluation class (M = 57.42, SD = 15.90) whom were 
statistically similar. Although the Chi-Square tests did not reach significance for parental status, self-
reported health and spiritual beliefs, the standardised adjusted residuals hinted that those in the 
autonomy focused class were less likely to have children (z = 1.7), more likely to be students (z = 1.7) 
and were more likely to report being in very good health (z = 2.3). There was also a suggestion that 
those in the result evaluation class were more likely to report that spiritual beliefs were not very 
important in their life (z – 1.8). 
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In summary, the research focused class (Class 1) tended to be older retired males from NT, the result 
evaluation class (Class 2) consisted of older people, not from NSW, with a university education and 
who placed low importance on spirituality, and the autonomy class (Class 3) tended to be younger 
people from NSW with a university degree, students and with a tendency towards very good health 
and not being parents. There were no significant differences across the classes in relation to marital 
status, and whether or not they were Australian born. 
Discussion 
The results of this research are broadly consistent with international data from the Scandinavia(18,19), 
the United Kingdom(17) and the United States(24) and suggest that the majority of the Australian public 
would be interested in receiving IRRs and IFs if they allowed their blood/tissue to be used in 
research. Specifically, 94.4% reported that they would like to receive specific information that may 
be important to your health or treatment, while 83.4% expressed a desire to be informed about their 
potential genetic risk of an inherited disease. Although less people expressed a desire to receive “any 
IFs that were not directly related to your (potential) diagnosed condition”, most (70%) still wished to 
be informed about IFs. 
 
Overall, the results of this study make clear that the majority of people want to know about most 
types of research results – including the overall results of the research, individual research results 
that may be relevant to the person’s current and future health and any incidental findings arising 
from the research. The results also reveal that it is difficult to make broad assumptions about the 
public preferences for disclosure (beyond the assumption that people generally wish to be informed) 
as the LCA suggested people may differ in regards to what they wish to know about research results 
that may be less salient to them – such as the overall results of research or, to incidental findings 
arising from the research. 
 
A number of limitations may restrict the generalisation of our research results and their translation 
into policy and practice. First, the specific results published in this paper reflect responses to only 4 
specific questions regarding the return of research results (forming part of a more comprehensive 
survey exploring general public willingness to donate and attitudes towards ethical issues around 
biobank related genomic research). Undeniably, more nuanced questions and response categories 
would provide a deeper understanding of general public attitudes towards disclosure. All 
respondents were asked to indicate their willingness to take part in a brief follow up interview 
concerning their responses to the survey items and the majority of respondents (67%) indicating 
their willingness to participate in further research (findings from this qualitative study will be 
published in the near future).  
 
The results from this,first national study of public attitudes and expectations to the return of 
research results and other ethico-legal issues relating to biobanks in Australia, nonetheless, provide a 
valuable account of public attitudes and a useful basis for further research. Secondly, it could be 
argued that the sample reflects the responses of only 800 Australians and is not representative of 
the general public. Further mixed-methods research would certainly establish the veracity and 
generalizability of our findings and we obtained the support from over 63% of respondents to 
participate in a brief follow up interview concerning their responses in the future.  We also sought to 
deal with the response bias that characterizes CATI surveys by weighting the data for age and gender 
in line with census data. While this response rate appears relatively low, this is typical for Australian 
national surveys conducted via CATI, random digit dialing (RDD) and ‘cold-calling’ members of the 
Australian public without introductory letters (which range from 15-25%).  Thus, while this research 
raises a series of further questions for study, the results presented here point to the need to think 
deeply about the way that we manage IRRs and IFs from biobank related genomic research in the 
future. 
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There are two major implications of this research. The first is that if people generally wish to be 
informed, but differ in what information they wish to know – then researchers who use 
biospecimens and biobank professionals need to establish policies and practices (including through 
information and consent forms) for establishing the information needs of tissue donors. The second 
is that clear strategies need to be established for determining what information derived from 
research, including both IRRs and IFs, may be of ‘value’ and how, and to whom, this information 
should be delivered. 
 
CONCLUSION   
The management of the results from translational genomic research in a consistent and clinically 
appropriate manner is already creating a practical challenge for clinical genetics services and for 
research biobanks around Australia and internationally. This challenge is likely to become 
increasingly problematic as genomic research expands, data linkage is adopted with greater 
enthusiasm and the amount of data generated by research increases. As more and more data is 
generated and interpreted to be of clinic significance, the question of defining significance and then 
acting upon such information in a manner expected by biobank donors, cancer patients and the 
community is paramount. It is crucial, therefore, that policies and processes are developed for the 
return of IRRs and IFs that are clinically appropriate and are consistent with the needs and 
expectations of biobank donors, patients and the general community. 
 
The decisions we make about the disclosure and management of IRRs and IFs, both at a policy level 
and in relation to individual donors, are not however, simply a matter of science, epidemiology or 
medicine, as data only becomes ‘evidence’, or becomes important, when it is given value – 
irrespective of whether this value is attached by researchers, clinicians, policy-makers or patients 
and their families. It is vital, therefore, that policy development in this area is democratic, evidence-
based and explicitly acknowledges the important ethical principles at stake, including autonomy, 
reciprocity and solidarity. Reassuringly, important research and policy reform is already being done 
in this area – with Australian oncology biobanks (20,25) recently outlining a number of models and 
practical strategies for managing disclosure of IRRs and IFs which aim to preserve and respect the 
autonomy of biobank donors while at the same time acknowledging the necessity for scientific 
judgements to be made about the utility and importance of research findings in different clinical and 
research settings. Similar research and policy development continues internationally, including by 
the American College of Clinical Genetics and Genomics (ACMG), the Association for Molecular 
Pathology (AMP), the NIH funded International Sarcoma Kindred Study group, the Presidential 
Commission for the Study of Bioethical Issues and the UK Biobank.  
 
The results of this study are important because they provide data that may inform the development 
of practical disclosure strategies by oncology biobanks and complement recent policy responses – 
notably the NHMRC National Statement 2007 guidelines (sections 3. 4.10, 3.5.1 – 2 inc.) the 
NHMRC’s National Biobanking Strategy and Targeted Consultation on the Return of Results from 
‘Omics’ based Research and Clinical Practice (2013) developed by the Human Genetics Advisory 
Commission (HGAC) and the Australian Health Ethics Committee (AHEC)(26,1).  More generally, 
however, this research provides clear evidence that knowledge gained in the course of research is 
valuable, in different ways to different stakeholders, and that advances in genomic research will be 
most likely to be successfully, and to be publicly supported, when the structures that support it are 
scientifically robust, clinically relevant and ethically sound. 
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